Gilead Sciences (NASDAQ:GILD) (NASDAQ:GILD) is a biopharmaceutical company headquartered in Foster City, California, that focuses on the discovery, development and commercialization of innovative medicines. Since its founding in 1987 by Dr. Michael L. Riordan, Gilead has built a global presence with operations in North America, Europe, Asia and emerging markets. The company employs a research-driven model, investing heavily in clinical development and regulatory approvals to address unmet medical needs in viral and oncology therapeutics.
Gilead’s core business activities center on antiviral therapies, particularly for HIV and hepatitis C. Flagship products include Biktarvy and Descovy for HIV prevention and treatment, and Sovaldi and Harvoni for hepatitis C. In response to the COVID-19 pandemic, Gilead secured emergency use authorization for Veklury (remdesivir), an antiviral treatment that has been administered globally. Beyond antivirals, the company is expanding into oncology and inflammatory diseases, with cell therapy products such as Yescarta and Tecartus, which leverage CAR T technology to target specific cancers.
Over the years, Gilead has pursued strategic acquisitions and partnerships to bolster its pipeline. Notable transactions include the acquisition of Pharmasset in 2011, which fueled its hepatitis C franchise, and the purchase of Kite Pharma in 2017, establishing a foothold in cell therapy. The company supports a broad R&D network with centers in the U.S., Europe and Asia, collaborating with academic institutions, biotech firms and global health organizations to accelerate innovation.
Leadership at Gilead is guided by CEO Daniel O’Day, who joined the company in 2019 and brings experience from global healthcare organizations. Under his direction, Gilead has emphasized scientific rigor, operational efficiency and patient access initiatives. The company’s diverse executive team and board of directors maintain a strategic focus on sustainable growth, ethical conduct and advancing therapies that improve patient outcomes worldwide.
